Turn Therapeutics Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a TTRX research report →
Price Chart
About the company
Turn Therapeutics Inc. , officially known as Global Health Solutions, Inc. , is a pharmaceutical enterprise dedicated to developing treatments for conditions affecting the skin, nails, and eyes.
- CEO
- Bradley E. Burnam
- IPO
- 2025
- Employees
- 2
- HQ
- Westlake Village, CA, US
Get TickerSpark's AI analysis on TTRX
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $284.18M
- P/E
- -32.74
- PEG
- 0.35
- P/S
- 0.00
- P/B
- 413.72
- EV/EBITDA
- -67.19
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -280.41%
- ROIC
- -84.66%
Latest fiscal year · YoY change
- Revenue
- $0+0.0%
- Gross Profit
- $0+0.0%
- Op Income
- $-5,858,648
- Net Income
- $-3,194,080-80.6%
- EPS
- $-0.23-76.9%
- OCF Growth
- -88.3%
- FCF Growth
- -85.9%
- 52W High
- $26.50
- 52W Low
- $2.57
- 50D MA
- $8.35
- 200D MA
- $5.00
- Beta
- 2.02
- RSI (14)
- 53
- Avg Volume
- 81.92K
No earnings-call transcripts are available for TTRX yet.
- Free Float
- 36.4%
- Shares Outstanding
- 29.79M
- Float Shares
- 10.83M
of shares held by institutions
22 13F filers
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Vanguard Group Inc | 30.16K | ▲ 30.16K |
Held by 19 ETFs
Biggest fund positions in TTRX by dollar value.
Our TTRX coverage
Recent articles, reports, and earnings notes.
No research on TTRX yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate TTRX report →Turn Therapeutics Announces New Peer-Reviewed Research Showing GX-03 Selectively Reduces Key Drivers of Skin Inflammation and Itch
gurufocus.com · Aug 20
Turn Therapeutics Announces New Peer-Reviewed Research Showing GX-03 Selectively Reduces Key Drivers of Skin Inflammation and Itch
businesswire.com · Aug 20
Turn Therapeutics Provides Corporate Updates and Reports Second Quarter 2026 Financial Results
businesswire.com · Aug 12
Turn Therapeutics to Ring the Nasdaq Closing Bell on Monday, August 10, 2026
gurufocus.com · Jul 28
Turn Therapeutics to Ring the Nasdaq Closing Bell on Monday, August 10, 2026
businesswire.com · Jul 28
Turn Therapeutics Refines GX-03 Eczema Trial After Interim Data, Eyes 2026 Readout
marketbeat.com · Jul 11
Why Is Turn Therapeutics Stock Trading Higher Today?
benzinga.com · Jul 7
Turn Therapeutics Announces Final Stage 2 Design and Data-Driven Expansion of GX-03 Phase 2 Program in Atopic Dermatitis
businesswire.com · Jul 7
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.